Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
https://www.zacks.com/stock/news/2282326/novartis-nvs-reports-positive-long-term-data-on-csu-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282326
May 31, 2024 - Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
0
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
https://www.zacks.com/stock/news/2279713/novartis-nvs-presents-positive-data-on-renal-drugs-at-era?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2279713
May 27, 2024 - Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
0
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
https://www.zacks.com/stock/news/2277986/biogen-biib-to-buy-hi-bio-to-expand-rare-disease-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277986
May 23, 2024 - Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2276619/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2276619
May 21, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
2 Magnificent Dividend Stocks to Hold for the Next Decade
https://www.fool.com/investing/2024/05/05/2-magnificent-dividend-stocks-to-hold-for-the-next/?source=iedfolrf0000001
May 05, 2024 - The dividend is just one reason to buy these stocks.
0
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2265278/incyte-s-incy-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2265278
Apr 30, 2024 - Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
0
Top Analyst Reports for Novartis, American Express & ConocoPhillips
https://www.zacks.com/commentary/2259373/top-analyst-reports-for-novartis-american-express-conocophillips?cid=CS-ZC-FT-research_daily-2259373
Apr 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
0
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/04/17/2-high-yield-dividend-stocks-to-hold-for-10-years/?source=iedfolrf0000001
Apr 17, 2024 - These income stocks look like good options at current levels.
0
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
https://www.fool.com/investing/2024/04/14/looking-for-an-easy-way-to-earn-passive-income-thi/?source=iedfolrf0000001
Apr 14, 2024 - Think globally with this high-yielding ETF.
0
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
https://www.zacks.com/stock/news/2254812/novartis-nvs-inks-deal-for-arvn-s-prostate-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254812
Apr 12, 2024 - Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
0